AMVUTTRA
Total Payments
$10.0M
Transactions
12,876
Doctors
5,181
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.8M | 6,907 | 3,223 |
| 2023 | $3.0M | 5,254 | 2,657 |
| 2022 | $2.2M | 715 | 394 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.7M | 467 | 66.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.0M | 597 | 20.4% |
| Food and Beverage | $439,775 | 10,673 | 4.4% |
| Space rental or facility fees (teaching hospital only) | $430,788 | 126 | 4.3% |
| Travel and Lodging | $254,497 | 929 | 2.6% |
| Consulting Fee | $148,742 | 67 | 1.5% |
| Education | $460.19 | 17 | 0.0% |
Payments by Type
Research
$6.7M
467 transactions
General
$3.3M
12,409 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Alnylam Pharmaceuticals Inc. | $3.1M | 0 |
| HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | Alnylam Pharmaceuticals Inc. | $2.3M | 0 |
| HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) | Alnylam Pharmaceuticals Inc. | $1.1M | 0 |
| Exploratory biomarker analysis and NfL assessment in patients with wtATTR amyloidosis with cardiomyopathy | Alnylam Pharmaceuticals Inc. | $109,237 | 0 |
Top Doctors Receiving Payments for AMVUTTRA — Page 206
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Interventional Cardiology | Toms River, NJ | $13.44 | 1 |
| , M.D | Interventional Cardiology | Toms River, NJ | $13.44 | 1 |
| , M.D | Hematology & Oncology | Chandler, AZ | $13.43 | 1 |
| , PA-C | Medical | Concord, CA | $13.42 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | San Pablo, CA | $13.42 | 1 |
| , MD | Neurology | Walnut Creek, CA | $13.40 | 1 |
| , MD | Neurology | Walnut Creek, CA | $13.40 | 1 |
| Aurora Lee | Physician Assistant | Walnut Creek, CA | $13.40 | 1 |
| , MD | Neurology | Walnut Creek, CA | $13.40 | 1 |
| , PA-C | Medical | Dakota Dunes, SD | $13.34 | 1 |
| , M.D | Neurology | Roseburg, OR | $13.34 | 1 |
| , PA C | Nephrology | Dakota Dunes, SD | $13.34 | 1 |
| , PA-C | Physician Assistant | Eatontown, NJ | $13.32 | 1 |
| Michael Wappel | Cardiovascular Disease | Eatontown, NJ | $13.32 | 1 |
| , DNP, APN-BC | Primary Care | Freehold, NJ | $13.32 | 1 |
| , MD | Neurology | Kankakee, IL | $13.30 | 1 |
| , MD | Neurology | Kankakee, IL | $13.30 | 1 |
| , FNP-C | Nurse Practitioner | White Bear Lake, MN | $13.28 | 1 |
| , P.A.-C | Medical | White Bear Lake, MN | $13.28 | 1 |
| , MD | Internal Medicine | White Bear Lake, MN | $13.28 | 1 |
| , DO | Internal Medicine | Phoenix, AZ | $13.25 | 1 |
| , M.D | Cardiovascular Disease | Mesa, AZ | $13.23 | 1 |
| , M.D | Cardiovascular Disease | Roseburg, OR | $13.19 | 1 |
| , MD | Cardiovascular Disease | Roseburg, OR | $13.19 | 1 |
| , M.D | Cardiovascular Disease | Belleville, NJ | $13.11 | 1 |
Ad
Manufacturing Companies
- Alnylam Pharmaceuticals Inc. $10.0M
Product Information
- Type Drug
- Total Payments $10.0M
- Total Doctors 5,181
- Transactions 12,876
About AMVUTTRA
AMVUTTRA is a drug associated with $10.0M in payments to 5,181 healthcare providers, recorded across 12,876 transactions in the CMS Open Payments database. The primary manufacturer is Alnylam Pharmaceuticals Inc..
Payment data is available from 2022 to 2024. In 2024, $4.8M was paid across 6,907 transactions to 3,223 doctors.
The most common payment nature for AMVUTTRA is "Unspecified" ($6.7M, 66.8% of total).
AMVUTTRA is associated with 4 research studies, including "HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy" ($3.1M).